Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic to Provide PGx Services to Two Drug Developers

NEW YORK (GenomeWeb News) - Transgenomic said yesterday that it has struck agreements with two undisclosed pharmaceutical companies to provide genetic mutation discovery services for two Phase II clinical trials.

The company said the deals will be worth a total of $500,000 in the first half of 2008, but it did not disclose the names of the companies involved or provide further financial details.

Transgenomic offers molecular clinical reference lab and pharmacogenomics research services, including mutation scanning tests for more than 700 genes linked to cancer and over 60 diagnostic tests.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.